Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical......
Narcolepsy affects 1 in every 2,000 Americans and 3 million people worldwide.
It is estimated that up to 50% of patients with Narcolepsy may be undiagnosed.
Typical onset of Narcolepsy is between the ages of 10 and 20 years old, but can occur in early childhood.
On average, patients have 6 physician visits before receiving a Narcolepsy diagnosis.
Online Support GroupsFree, online support groups worldwide for people with Narcolepsy and their families. |
National SummitThis one-day summit is for people with Narcolepsy, their families, educators, clinicians and researchers. |
Clinical TrialsPatient engagement in clinical trials help find new ways to treat individuals with Narcolepsy. |
Annual Family WeekendChildren & Teens with Narcolepsy can meet others experiencing the same symptoms and challenges. |
Join Our TeamDo you share our passion for advocating on behalf of those with Narcolepsy? |
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical......
The final WUN Town Hall of 2024 took place on November 16th in Cincinnati, Ohio! ......
GivingTuesday is a global generosity movement where donors and nonprofits team up to transform their......
The Syracuse WUN Town Hall took place on November 9th in Baldwinsville, New York! The......